

JW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Carl June Serial No: 10/681,627 Filed: October 8, 2003 For: METHODS FOR MODULATING T CELL RESPONSES BY MANIPULATING INTRACELLULAR SIGNAL TRANSDUCTION	Group Art Unit: 1633 Attorney Docket No.: WYS-014.02 Examiner: A. Wehbe
--	---

CERTIFICATE OF MAILING/TRANSMISSION

I hereby certify that the correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 18, 2006.



Katelyn Nelson

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION-DISCLOSURE STATEMENT

UNDER 37 CFR 1.97(b)(3)


Applicant hereby brings to the Examiner's attention the references listed on the accompanying form PTO-1449. Copies of references CA-CL listed on the attached PTO form 1449 are enclosed. Applicant respectfully requests that the Examiner consider the cited references and indicate that each reference cited was considered by making appropriate notations on the attached form.

Applicant has listed the date of publication on the attached PTO-1449 for each cited document based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited document was actually published or otherwise publicly available on the date indicated.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that any or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited document(s) do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such document(s). Moreover, Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This Information Disclosure Statement is being filed before the mailing of a first Office action on the merits, and therefore no fees are believed to be due in connection with this submission. The Director is hereby authorized to charge any deficiency that should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-1448, under Reference No. WYS-014.02.

Date: September 18, 2006
155 Seaport Boulevard
Boston, MA 02210
Telephone: (617) 832-1000
Telecopier: (617) 832-7000

Respectfully submitted,
Foley Hoag LLP

By: _____
DeAnn F. Smith
Reg. No. 36,683
Attorney for Applicant



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/681,627-Conf. #7408
				Filing Date	October 8, 2003
				First Named Inventor	Carl H. June
				Art Unit	1633
				Examiner Name	A. M. S. Wehbe
Sheet	1	of	1	Attorney Docket Number	WYS-014.02

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	CA	Augustine J. A. et al., "Interleukin 2- and Polyomavirus Middle T Antigen-Induced Modification of Phosphatidylinositol 3-Kinase Activity in Activated T Lymphocytes." Molecular and Cellular Biology, 1991, Vol. 11, No.9, p. 4431-4440.				
	CB	Davies A. A. et al., "The Human T3y Chain Is Phosphorylated at Serine 126 in Response to T Lymphocyte Activation." The Journal of Biological Chemistry, 1987, Vol. 262, No. 23, p.10918-10921.				
	CC	Graber M. et al., "The Protein Tyrosine Kinase Inhibitor Herbimycin A, but not Genistein, Specifically Inhibits Signal Transduction by the T Cell Antigen Receptor." International Immunology, 1992, Vol. 4, No. 11, p. 1201-1210.				
	CD	June C. H. et al., "Inhibition of Tyrosine Phosphorylation Prevents T-cell Receptor Mediated Signal Transduction." Proc. Natl Acad. Sci. USA, 1990, Vol. 87, p. 7722-7726.				
	CE	Merida I. et al., "IL-2 Binding Activates a Tyrosine-Phosphorylated Phosphatidylinositol-3-Kinase." The Journal of Immunology, 1991, Vol. 147, p. 2202-2207.				
	CF	Prasad K. V. S. et al., "T-cell Antigen CD28 Interacts with the Lipid Kinase Phosphatidylinositol 3-kinase by a Cytoplasmic Tyr(P)-Met-Xaa-Met Motif." Proc. Natl. Acad. Sci. USA, 1994, Vol. 91, p. 2834-2838.				
	CG	Reif K. et al., "Divergent Regulation of Phosphatidylinositol 3-Kinase P85α and P85β Isoforms upon T Cell Activation." The Journal of Biological Chemistry, 1993, Vol. 268, No. 15, p. 10780-10788.				
	CH	Shibasaki F. et al., "Different Properties of Monomer and Heterodimer Forms of Phosphatidylinositol 3-kinases." Biochem. J., 1993, Vol. 289, p. 227-231.				
	CI	Thompson P. A. et al., "Identification of Distinct Populations of PI-3 Kinase Activity Following T-Cell Activation." Oncogene, 1992, Vol. 7, p. 719-725.				
	CJ	Torimoto, T. et al. "CD45 Molecule and T Cell Activation." 1990. Vol. 27, p. 63-71.				
	CK	Vlahos C. J. et al., "A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)." The Journal of Biological Chemistry, 1994, Vol. 269, No. 7, p. 5241-5248.				
	CL	Woscholski R. et al., "A Comparison Of Demethoxyviridin And Wortmannin As Inhibitors Of Phosphatidylinositol 3-Kinase." FEBS Letters, 1994, Vol.342, p. 109-114.				

Examiner Signature	Date Considered
--------------------	-----------------